Saracatinib
Based on 43 publication(s) in Google Scholar
Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.23%
- CAS No.: 379231-04-6
- Formule: C27H32ClN5O5
- Masse moléculaire:542.03
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Kinase Inhibitor Library
HY-L009
-
Protein Tyrosine Kinase Compound Library
HY-L016
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Autophagy Compound Library
HY-L029
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
Anti-COVID-19 Compound Library
HY-L052
-
Orally Active Compound Library
HY-L061
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Angiogenesis-Related Compound Library
HY-L088
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Membrane Protein-targeted Compound Library
HY-L149
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Kinase Inhibitor Library Mini
HY-L009M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) Saracatinib
More- Signal Transduct Target Ther. 2023 Feb 17;8(1):66. [Abstract]
- Cancer Res. 2024 Feb 1;84(3):479-492. [Abstract]
- Nat Commun. 2025 Apr 7;16(1):3319. [Abstract]
- Nat Commun. 2023 Apr 24;14(1):2342. [Abstract]
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Neuro Oncol. 2026 Jan 7:noaf297. [Abstract]
- Cell Death Dis. 2025 Feb 3;16(1):64. [Abstract]
- Cell Death Dis. 2021 Dec 3;12(12):1126. [Abstract]
- Cell Death Dis. 2020 Aug 7;11(8):652. [Abstract]
- Int J Biol Sci. 2025 Mar 31;21(6):2780-2805. [Abstract]
- Phytomedicine. 2025 Oct 8:148:157387. [Abstract]
- EBioMedicine. 2022 Dec:86:104374. [Abstract]
- Acta Neuropathol. 2025 May 14;149(1):48. [Abstract]
- J Orthop Translat. 2022 Feb 16:33:55-69. [Abstract]
- Leukemia. 2012 Oct;26(10):2233-44. [Abstract]
- Int J Biol Macromol. 2026 May 27:152746. [Abstract]
- Int J Biol Macromol. 2026 Jan:336:149150. [Abstract]
- Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696. [Abstract]
- Cell Rep. 2022 Mar 8;38(10):110462. [Abstract]
- Cell Prolif. 2023 Jan;56(1):e13337. [Abstract]
- Cancer Cell Int. 2021 Dec 7;21(1):655. [Abstract]
- Mol Cancer Ther. 2017 Nov;16(11):2387-2398. [Abstract]
- Biochem Pharmacol. 2026 Aug;250(Pt 2):118028. [Abstract]
- Biochem Pharmacol. 2026 Jun 25;251(Pt 2):118189. [Abstract]
- Biochem Pharmacol. 2025 Jun 2:239:117014. [Abstract]
- Int J Mol Sci. 2021 Aug 27;22(17):9289. [Abstract]
- Cancer Sci. 2018 Jun;109(6):1949-1957. [Abstract]
- Cell Signal. 2025 Mar 29:111781. [Abstract]
- J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]
- Oncol Rep. 2018 Aug;40(2):635-646. [Abstract]
- iScience. 2022 Sep 19;25(10):105171. [Abstract]
- J Virol. 2026 Apr 21;100(4):e0024126. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Arch Biochem Biophys. 2018 May 1:645:54-60. [Abstract]
- Res Sq. 2026 May 20.
- Preprints. 2025 Sep 22.
- bioRxiv. 2024 Nov 6:2024.11.04.621884. [Abstract]
- bioRxiv. 2024 July 09.
- bioRxiv. 2023 Dec 14.
- Biomed Pharmacother. 2021 Dec 6;146:112487. [Abstract]
- Research Square Preprint. 2021 Jul.
- Technical University of Munich. 24.01.2018.
- Oncotarget. 2015 Sep 29;6(29):27160-75. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
WB
Activité biologique
IC50: 2.7 nM (Src), 30 nM (v-Abl), 66 nM (EGFR), 200 nM (c-Kit)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
0.14 μM
Compound: 33, AZD-0530
|
Inhibition of A549 cell migration by microdroplet migration assay
Inhibition of A549 cell migration by microdroplet migration assay
|
[PMID: 17064066] |
| HeLa | IC50 |
2.4 μM
Compound: 30
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth inhibition
Antiproliferative activity against human HeLa cells assessed as reduction in cell growth inhibition
|
[PMID: 32539378] |
| Huh-7 | CC50 |
>50 μM
Compound: 46
|
Cytotoxicity against human Huh-7 cells
Cytotoxicity against human Huh-7 cells
|
[PMID: 32283298] |
| Huh-7 | CC50 |
>50 μM
Compound: Saracatinib
|
Cytotoxicity against human Huh-7 cells
Cytotoxicity against human Huh-7 cells
|
[PMID: 34081439] |
| Huh-7 | CC50 |
74 μM
Compound: 43; AZD0530
|
Cytotoxicity against human Huh-7 cells
Cytotoxicity against human Huh-7 cells
|
[PMID: 33539089] |
| HUVEC | IC50 |
>5 μM
Compound: 33, AZD-0530
|
Inhibition of FGF-stimulated HUVEC cell growth
Inhibition of FGF-stimulated HUVEC cell growth
|
[PMID: 17064066] |
| HUVEC | IC50 |
>5 μM
Compound: 33, AZD-0530
|
Inhibition of VEGF-stimulated HUVEC cell growth
Inhibition of VEGF-stimulated HUVEC cell growth
|
[PMID: 17064066] |
| K562 | IC50 |
220 nM
Compound: 33, AZD-0530
|
Antiproliferative activity against huamn K562 cell line
Antiproliferative activity against huamn K562 cell line
|
[PMID: 17064066] |
| NIH3T3 | IC50 |
0.0027 μM
Compound: 33, AZD-0530
|
Inhibition of human c-Src in NIH3T3 cells
Inhibition of human c-Src in NIH3T3 cells
|
[PMID: 17064066] |
| NIH3T3 | IC50 |
0.076 μM
Compound: 33, AZD-0530
|
Antiproliferative activity against mouse NIH3T3 cell line transfected with c-SRC
Antiproliferative activity against mouse NIH3T3 cell line transfected with c-SRC
|
[PMID: 17064066] |
| SJRH30 | IC50 |
10.1 μM
Compound: 2, NCGC00241099
|
Antiproliferative activity against human Rh30 cells after 48 hrs by CellTiter-Glo luminescent assay
Antiproliferative activity against human Rh30 cells after 48 hrs by CellTiter-Glo luminescent assay
|
[PMID: 23787099] |
| Vero | CC50 |
>50 μM
Compound: 30
|
Cytotoxicity against African green monkey Vero cells by MTT assay
Cytotoxicity against African green monkey Vero cells by MTT assay
|
[PMID: 32539378] |
| Vero C1008 | EC50 |
10 μM
Compound: Saracatinib
|
Antiviral activity against MERS-CoV infected in african green monkey Vero E6
Antiviral activity against MERS-CoV infected in african green monkey Vero E6
|
[PMID: 37597435] |
Saracatinib (AZD0530), an orally available Src inhibitor, demonstrates potent antimigratory and anti-invasive effects in vitro, and inhibits metastasis in a murine model of bladder cancer. Antiproliferative activity of Saracatinib varies between cell lines (IC50 of 0.2-10 μM). Saracatinib potently inhibits the proliferation of Src3T3 mouse fibroblasts and demonstrates variable antiproliferative activity in a range of human cancer cell lines containing endogenous Src. Sub micromolar growth inhibition of five of the human cancer cell lines tested with Saracatinib (tumor types: colon, prostate, lung, and leukemia) is observed with IC50 values of 0.2-0.7 μM. In 3-day MTS cell proliferation assays, Saracatinib inhibits proliferation of the Bcr-Abl-driven human leukemia cell line K562 with an IC50 of 0.22 μM. In the microdroplet migration assay, Saracatinib reduces the migration of human lung cancer A549 cells in a concentration-dependent manner (IC50 0.14 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 379231-04-6
-
Appearance Solid
-
Masse moléculaire 542.03
-
Formule C27H32ClN5O5
-
Color White to light yellow
-
SMILES
ClC1=CC=C2C(OCO2)=C1NC3=C4C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=CC4=NC=N3
-
Synonyms
AZD0530
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (43)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with β-catenin. [Abstract]2023 Feb 17;8(1):66. PMID: 36797256
Saracatinib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Feb 17;8(1):66. [Abstract]
Saracatinib (10 μM) reduces BLK-mediated FAM83A tyrosine phosphorylation in HEK293T cells.
-
Cancer Res
Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem/progenitor cells. [Abstract]2024 Feb 1;84(3):479-492. PMID: 38095536 -
Nat Commun
p38 mediated ACSL4 phosphorylation drives stress-induced esophageal squamous cell carcinoma growth through Src myristoylation. [Abstract]2025 Apr 7;16(1):3319. PMID: 40195298 -
Nat Commun
TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. [Abstract]2023 Apr 24;14(1):2342. PMID: 37095176 -
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Neuro Oncol
MBD3 deficiency decommissions the NuRD complex and orchestrates the epigenetic regulation of gene expression to suppress neuroblastoma progression. [Abstract]2026 Jan 7:noaf297. PMID: 41499431 -
Cell Death Dis
Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway. [Abstract]2025 Feb 3;16(1):64. PMID: 39900894 -
Cell Death Dis
Hippo signaling suppresses tumor cell metastasis via a Yki-Src42A positive feedback loop. [Abstract]2021 Dec 3;12(12):1126. PMID: 34862372 -
Cell Death Dis
FYN is required for ARHGEF16 to promote proliferation and migration in colon cancer cells. [Abstract]2020 Aug 7;11(8):652. PMID: 32811808 -
Int J Biol Sci
Macrophage KDM2A promotes atherosclerosis via regulating FYN and inducing inflammatory response. [Abstract]2025 Mar 31;21(6):2780-2805. PMID: 40303308 -
Phytomedicine
Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer. [Abstract]2025 Oct 8:148:157387. PMID: 41106095 -
EBioMedicine
Heat shock protein amplification improves cerebellar myelination in the Npc1nih mouse model. [Abstract]2022 Dec:86:104374. PMID: 36455410 -
Acta Neuropathol
2025 May 14;149(1):48. PMID: 40366450 -
J Orthop Translat
Puerarin specifically disrupts osteoclast activation via blocking integrin-β3 Pyk2/Src/Cbl signaling pathway. [Abstract]2022 Feb 16:33:55-69. PMID: 35228997 -
Leukemia
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. [Abstract]2012 Oct;26(10):2233-44. PMID: 22469781 -
Int J Biol Macromol
SLC39A1 promotes pancreatic cancer metastasis by elevating intracellular zinc and activating the Src/FAK signaling pathway. [Abstract]2026 May 27:152746. PMID: 42208832 -
Int J Biol Macromol
Laminin β1 stimulates the Hippo-YAP1 pathway to advance the progression and lenvatinib resistance in hepatocellular carcinoma. [Abstract]2026 Jan:336:149150. PMID: 41274476 -
Cell Mol Gastroenterol Hepatol
2021;11(3):683-696. PMID: 33075564 -
Cell Rep
Nociceptor-derived Reg3γ prevents endotoxic death by targeting kynurenine pathway in microglia. [Abstract]2022 Mar 8;38(10):110462. PMID: 35263589 -
Cell Prolif
PFKFB4 facilitates palbociclib resistance in oestrogen receptor-positive breast cancer by enhancing stemness. [Abstract]2023 Jan;56(1):e13337. PMID: 36127291 -
Cancer Cell Int
Attenuated expression of SNF5 facilitates progression of bladder cancer via STAT3 activation. [Abstract]2021 Dec 7;21(1):655. PMID: 34876150 -
Mol Cancer Ther
Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. [Abstract]2017 Nov;16(11):2387-2398. PMID: 28775147 -
Biochem Pharmacol
Divergent mechanisms, unified therapy: saracatinib targets Src/HIF signaling in endothelial and microglial cells to treat retinopathy. [Abstract]2026 Aug;250(Pt 2):118028. PMID: 42070593 -
Biochem Pharmacol
2026 Jun 25;251(Pt 2):118189. PMID: 42349620 -
Biochem Pharmacol
IFITM1 promotes proliferation, migration and macrophage-like transdifferentiation of vascular smooth muscle cells via c-Src/MAPK/GATA2/E2F2 pathway in atherosclerosis. [Abstract]2025 Jun 2:239:117014. PMID: 40466954 -
Int J Mol Sci
2021 Aug 27;22(17):9289. PMID: 34502195 -
Cancer Sci
2018 Jun;109(6):1949-1957. PMID: 29601121 -
Cell Signal
Annexin A2 binds the 3'-UTR of H2AX mRNA and regulates histone-H2AX-derived hypoxia-inducible factor 1-alpha activation. [Abstract]2025 Mar 29:111781. PMID: 40164417 -
J Cell Mol Med
Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion. [Abstract]2019 Apr;23(4):2399-2409. PMID: 30677226
Saracatinib purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Apr;23(4):2399-2409. [Abstract]
Immunoblot analysis of p-JNK1/2 (T183/Y185) in HepG2 cells treated with saracatinib (10 μM, 12 h) and PP1 (10 μM, 2 h).
-
Oncol Rep
Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. [Abstract]2018 Aug;40(2):635-646. PMID: 29917168 -
iScience
Inhibition of SRC-mediated integrin signaling in bone marrow niche enhances hematopoietic stem cell function. [Abstract]2022 Sep 19;25(10):105171. PMID: 36204266 -
J Virol
2026 Apr 21;100(4):e0024126. PMID: 41914886 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Arch Biochem Biophys
miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway. [Abstract]2018 May 1:645:54-60. PMID: 29550144
Saracatinib purchased from MedChemExpress. Usage Cited in: Arch Biochem Biophys. 2018 May 1:645:54-60. [Abstract]
SK-BR-3, MCF-7, and MDA-MB-231 cells are treated with 1 μM Saracatinib for 48 h. After treatment, the Src protein expression is determined by western blot.
-
-
-
bioRxiv
PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. [Abstract]2024 Nov 6:2024.11.04.621884. PMID: 39574568 -
-
-
Biomed Pharmacother
Periplocin ameliorates mouse age-related meibomian gland dysfunction through up-regulation of Na/K-ATPase via SRC pathway. [Abstract]2021 Dec 6;146:112487. PMID: 34883449 -
-
-
Oncotarget
2015 Sep 29;6(29):27160-75. PMID: 26320174
Solvant et solubilité
DMSO : 50 mg/mL (92.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Investigation of the reversibility and the mechanism of Saracatinib inhibition is conducted using a full-length activated human Src in a continuous, coupled assay. ATP and peptide substrate (Src II peptide) concentrations are varied in turn (ATP 40-1280 μM; Src II peptide 100-800 μM), in conjunction with Saracatinib (0-30 nM), at saturating concentrations of the non-varied substrate (ATP 1.6 mM; Src II peptide 1.0 mM). The binding affinity of Saracatinib for inactivated Src (phosphorylated at tyrosine 527, not tyrosine 416) is measured using a BIAcore inhibition-in-solution assay. The assay followed competition binding between Saracatinib and an immobilized ureidoquinazoline for binding to Src. Data analysis is performed by unweighted nonlinear regression using GraFit, version 5 and an F-test is used to identify the most suitable equation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell proliferation is assessed using a colorimetric 5-bromo-2′-deoxyuridine (BrdU) Cell Proliferation ELISA kit. Briefly, cells are plated onto 96-well plates (1.5×104 cells/well), the following day 0.039-20 μM Saracatinib in DMSO (at a final concentration of 0.5%) is added and the cells are incubated for 24 h. The cells are pulse labeled with BrdU for 2 h and fixed. Cellular DNA is then denatured with the provided solution and incubated with antiBrdU peroxidase for 90 min. Following three washes with phosphate-buffered saline, tetramethylbenzidine substrate solution is added and the plates are incubated on a plate shaker for 10-30 min until the positive control absorbance at 690 nm is approximately 1.5 absorbance units[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice and Rats[1]
Female athymic mice (nu/nu) and rats (RH-rnu/rnu) are used. Animals are treated once daily by oral gavage with either vehicle alone or Saracatinib 6.25-50 mg/kg for 10-91 days. Tumor growth inhibition is calculated. For pharmacokinetic and pharmacodynamic analysis animals are humanely sacrificed and samples (plasma and tumor) are collected. Tumor samples are homogenized with 5 volumes of water and extracted with chloroform. Plasma and tumor samples are analyzed for Saracatinib concentration using high-performance liquid chromatography with tandem mass spectrometric detection after solid-phase extraction.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3(3), 248-261. [Content Brief]
[2]. Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8449 mL | 9.2246 mL | 18.4492 mL | 46.1229 mL |
| 5 mM | 0.3690 mL | 1.8449 mL | 3.6898 mL | 9.2246 mL | |
| 10 mM | 0.1845 mL | 0.9225 mL | 1.8449 mL | 4.6123 mL | |
| 15 mM | 0.1230 mL | 0.6150 mL | 1.2299 mL | 3.0749 mL | |
| 20 mM | 0.0922 mL | 0.4612 mL | 0.9225 mL | 2.3061 mL | |
| 25 mM | 0.0738 mL | 0.3690 mL | 0.7380 mL | 1.8449 mL | |
| 30 mM | 0.0615 mL | 0.3075 mL | 0.6150 mL | 1.5374 mL | |
| 40 mM | 0.0461 mL | 0.2306 mL | 0.4612 mL | 1.1531 mL | |
| 50 mM | 0.0369 mL | 0.1845 mL | 0.3690 mL | 0.9225 mL | |
| 60 mM | 0.0307 mL | 0.1537 mL | 0.3075 mL | 0.7687 mL | |
| 80 mM | 0.0231 mL | 0.1153 mL | 0.2306 mL | 0.5765 mL |
Saracatinib Related Classifications
HY-10234 Related Classifications
Powered by Bioz